Basic Information
| LncRNA/CircRNA Name | TRPM2-AS |
| Synonyms | TRPM2-AS, TRPM2-AS1 |
| Region | GRCh38_21:44414588-44425272 |
| Ensemble | ENSG00000230061 |
| Refseq | NR_109964 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | Microarray, qPCR, RNAi etc. |
| Sample | prostate cancer tissues, cell lines (PNT1A, PC3 etc.) |
| Expression Pattern | up-regulated |
| Function Description | TRPM2-AS is overexpressed in prostate cancer (PCa). The high expression of TRPM2-AS and its related gene signature were found to be linked to poor clinical outcome, with the related gene signature working also independently of the patient's Gleason score. Mechanistically, TRPM2-AS knockdown led to PCa cell apoptosis, with a transcriptional profile that indicated an unbearable increase in cellular stress in the dying cells, which was coupled to cell cycle arrest, an increase in intracellular hydrogen peroxide and activation of the sense TRPM2 gene. |
| Pubmed ID | 24931166 |
| Year | 2014 |
| Title | Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer. |
External Links
| Links for TRPM2-AS | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |